Safety Evaluation of an Aqueous Extract of Termitomyces robustus (Agaricomycetes) in Wistar Rats.

Abstract

Termitomyces robustus is an edible and highly nutritious wild Basidiomycetes mushroom. It is used in ethnomedicine for treating malnutrition-related diseases, rheumatism, diarrhea, gonorrhea, anemia, and hypertension. Despite the tremendous use of this delicious edible mushroom as a source of nutrients, no comprehensive literature describes its safety and toxicity profiles. Therefore, this study evaluated the toxicity profile of an aqueous T. robustus extract in rats. In the acute toxicity test, male and female rats were orally administered daily a single dose of up to 10 g/kg extract. In the subacute toxicity test, male rats were orally administered the T. robustus extract at graded doses of 500, 1000, and 1500 mg/kg for 14 days. No mortality or any signs of toxicity were observed in the acute toxicity study, indicating that the median lethal dose (LD50) of T. robustus is greater than 10 g/kg. In the subacute toxicity study, T. robustus had no effect (P > 0.05) on hemoglobin, packed cell volume, red blood cell, white blood cell, alanine aminotransferase, alkaline phosphatase, neutrophil, lymphocyte, or lipid profile parameters in any of the rats. However, significant differences (P < 0.05) were noted in alanine aminotransferase, eosinophils, basophils, monocytes, platelets, urea, creatinine, and electrolytes in the tested groups when compared to values from the control group. No histopathological alterations or changes were observed in the liver or kidneys of the rats. This study established that an aqueous extract of T. robustus is nontoxic and therefore safe for consumption at the tested doses.